Search

everythinglearnresearchcommunity

for

Search:↓

The user is concerned about potential alopecia areata. They are seeking advice on whether this condition is normal.

The user underwent a hair transplant and was prescribed dutasteride and minoxidil for 6 months to address crown thinning. They are skeptical about the short duration and consider continuing the medication longer.

Post Finasteride Syndrome (PFS) may result from epigenetic changes and gut microbiota alterations. Supplementing with Allopregnanolone might protect against these adverse effects.

A woman with AGA and CTE has been taking multiple hair loss treatments including spironolactone, dutasteride, finasteride, bicalutamide, birth control, and minoxidil without success. Steroid injections, however, dramatically and immediately stopped her hair loss, though the effect lasts less than a month.

The impact of creatine on DHT levels, and whether it could cause accelerated male pattern baldness (MPB). The user taking a 5 alpha reductase inhibitor found that their DHT levels actually reduced despite taking creatine for nine weeks. Replies suggested looking into testosterone levels as well and debating the safety of creatine use in relation to MPB.

A user's experience with the hair loss treatment Pyrilutamide KX-826, which has resulted in some side effects and shedding. The conversation also includes advice for baseline pictures and trying treatments for at least 6 months.

The user experienced significant hair loss due to health issues and has only taken vitamins for recovery. They are seeking advice on regrowth progress after two months.

Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.

The conversation discusses the potential use of verteporfin for hair loss treatment, with one user mentioning their surgeon's interest in trying it and another noting its research status and clinical use as a YAP inhibitor. Some users debate the market size, availability of generics, and the optimism in the hair loss community regarding new treatments.

The conversation is about a transgender individual's experience with hair regrowth using topical minoxidil and hormone replacement therapy (HRT), expressing concern about the slow growth and thin appearance of their hair. Some responses encourage patience and highlight the variability of results, while others discuss the role of HRT and its effects.

A 21-year-old male with advanced hair loss (NW7) started using finasteride and minoxidil 10 months ago but hasn't seen much progress. He is pre-diabetic with stage 1 hypertension and is seeking insights on whether treating these conditions could improve hair regrowth.

A 33-year-old male is experiencing thinning at the temples and hairline, with increased shedding over the past year. The user suspects androgenetic alopecia (AGA) despite AI suggesting a maturing hairline.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

The conversation discusses the less impressive results of Pyrilutamide (kx-836) in phase 3 compared to phase 2, with a suggestion that a longer study might show more significant results. One user reports personal success with Pyrilutamide, experiencing no further hair loss and gradual regrowth.

The launch of Pyrilutamide as a potential hair loss treatment, with people discussing whether it is better than treatments like finasteride and minoxidil. Some participants have also discussed the risks associated with importing drugs from China.

Hair regrowth in transfems is more effective due to hormonal changes, specifically estrogen, which keeps hair in growth phase longer. Treatments mentioned include anti-androgens, sex hormones, and DHT blockers like finasteride.

The conversation discusses the effects of lowering DHT on hair loss and the importance of monitoring DHT levels during treatment. The user suggests that individual responses to DHT and hair loss treatments vary, and expresses a preference for topical treatments over oral medications due to concerns about systemic DHT reduction.

The user experienced heavy shedding 10 months after a hair transplant and used a topical solution of Minoxidil and Finasteride, later switching to Finoduta. They also dealt with a dry scalp and greasy hair, using various shampoos and conditioners, and sought advice on whether the shedding was normal and how to manage the dry scalp.

A user experiencing significant hair loss found they had a severe vitamin D deficiency and was prescribed 50,000IU vitamin D pills, likely to be taken weekly. They are questioning if the deficiency could be the cause of their hair loss and if correcting it could stop the shedding and improve hair recovery.

A user experienced hair thinning possibly due to excess vitamin A from taking extra gummy vitamins. They stopped taking the vitamins and are seeking advice on hair regrowth and managing vitamin A levels.

The user is using dutasteride, oral minoxidil, and topical minoxidil with tretinoin for hair loss. They are considering whether to continue this treatment or opt for a hair transplant for their temples.

The conversation discusses the use of 12.5mg cyproterone every other day for hair loss. There's a concern about reducing testosterone potentially increasing DHT and negatively affecting hair.

Balding scalps have more androgen receptors, leading to increased TGF-beta, which causes blood vessel loss and hair follicle miniaturization. Blocking androgen signaling and TGF-beta may help prevent hair loss.

A peptide-based hair loss treatment, PP405, reportedly increased hair density by 62% in 90 days, but these claims are unverified and met with skepticism. Users compared PP405 to Minoxidil and Finasteride, expressing doubts about its effectiveness without more evidence.

Hair loss treatments discussed include microneedling, minoxidil, tretinoin, finasteride, dutasteride, pumpkin seeds, saw palmetto, and scalp massage. The consensus is that finasteride or dutasteride is necessary for significant regrowth, while other methods may only slow hair loss.

The post discusses a phase 2 trial for HMI-115, a hair loss treatment, in China, specifically seeking volunteers aged 18-65 with Norwood 3 vertex, 4, and 5 hair loss. The conversation includes questions about the specific recruitment criteria and how to volunteer.

Pyrilutamide is being used effectively for hair loss with no side effects, and the user is seeking a cheaper bulk supplier. Users discuss the difficulty of finding affordable, trustworthy sources, with some suggesting potential suppliers.

PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.

The conversation discusses using cyproterone temporarily to reverse hair loss, followed by finasteride to maintain regrowth. Concerns about cyproterone's side effects, such as lowering testosterone and potential health risks, are raised, with alternatives like spironolactone suggested for androgen-related issues.

User with diffused thinning hair prefers receding temples, as hair transplant could fix it. Finasteride and minoxidil suggested to improve hair density.